Literature DB >> 9604126

The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers.

J M Cardot1, J B Lecaillon, C Czendlik, J Godbillon.   

Abstract

The effect of food on the pharmacokinetics of the antiepileptic rufinamide was investigated in healthy volunteers. Twelve subjects were treated with single pre-oral doses of 600 mg of rufinamide after overnight fasting or a fat and protein rich breakfast. Mean (+/- S.D.) areas under the plasma concentration-time curves (AUCs) of the unchanged compound were 57.2 (16) micrograms mL-1 h when given to the fasted volunteers and 81.7 (22.2) micrograms mL-1 h (p = 0.0001) when given after the breakfast. The average AUC was increased by 44% when rufinamide was given with food and the maximum concentration (Cmax) by about 100%. The time at which Cmax was reached (tmax) was shorter (8 h in fasted conditions and 6 h in fed after breakfast); the terminal half-life was not influenced by concomitant intake of food.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9604126     DOI: 10.1002/(sici)1099-081x(199805)19:4<259::aid-bdd98>3.0.co;2-v

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  9 in total

1.  Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.

Authors:  Mingzhen Xu; Yang Ni; Ying Zhou; Xiaomeng He; Huqun Li; Hui Chen; Weiyong Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

Review 2.  Rufinamide.

Authors:  Santiago Arroyo
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 3.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

4.  Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.

Authors:  Soonmo Peter Kang; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2010-08-24       Impact factor: 12.531

Review 5.  Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview.

Authors:  Heather Ann Wier; Ana Cerna; Tsz-Yin So
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 6.  Rufinamide.

Authors:  Emma D Deeks; Lesley J Scott
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 8.  Use of second-generation antiepileptic drugs in the pediatric population.

Authors:  Allison M Chung; Lea S Eiland
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy).

Authors:  Gerhard Kluger; Bettina Bauer
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.